


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-9 (cancelled)

10. (new) A method for restoring the apoptosis-indicating function of mutant p53 proteins in a mammal, comprising administering to said mammal in need thereof a compound selected from compounds having a structure according to the formula I




wherein:

R1 is hydrogen or a methylene group, which can be double bonded, as indicated by the broken line, or single bonded and linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and;

A is an oxygen-containing moiety, either consisting of an oxygen atom being double bonded, as indicated by the broken line, or a benzoyloxy group, with the proviso that when A is a benzoyloxy group, then R1 is hydrogen, and wherein said compound is not 9-(azabicyclo[2.2.2]octane-3-one)-6-chloro-9H.


11. (new) The method according to claim 10, wherein the compound is selected from 2-(adenine-9-methylene)-3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(-2-amino-3-chloro-5-trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-methylene)-3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone.
12. (new) The method according to claim 10, wherein the compound is selected from compounds having the structure of the general formula I'



wherein

R₁ is a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and, more preferably R₁ is a methylene group linked to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue.

13. (new) A method for restoring apoptosis-inducing function of mutant p53 proteins in a mammal, comprising:
administering to said mammal in need thereof an effective amount of 2-ethylene-4(3H)-quinazolinone.
14. (new) The method according to claim 10, wherein said compound is together with a pharmaceutically acceptable carrier, diluent and/or excipient.
15. (new) The method according to claim 10, wherein the mammal suffers from the mutant p53 mediated disease of cancer.
16. A method of treating a mutant p53 mediated disease, comprising administering to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I



wherein:

R₁ is hydrogen or a methylene group, which can be double bonded, as indicated by the broken line, or single bonded and linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and;

A is an oxygen-containing moiety, either consisting of an oxygen atom being double bonded, as indicated by the broken line, or a benzoyloxy group, with the

proviso that when A is a benzoyloxy group, then R1 is hydrogen.

17. The method of claim 7, wherein the mutant p53 mediated disease is cancer.